Isocitrate Dehydrogenase (IDH)

ZD-2767P is a reversible and competitive inhibitor of isocitrate dehydrogenase 1 (IDH1), with an IC50 value of 410 nM. This compound has been shown to effectively modulate IDH1 activity, making it a valuable tool for investigating metabolic pathways and oncogenic processes associated with IDH1 mutations. ZD-2767P is suitable for research applications focused on cancer biology and metabolic regulation.

Mutant IDH1/NAMPT-IN-1 is a dual inhibitor targeting mutant isocitrate dehydrogenase 1 (mutant IDH1) and nicotinamide phosphoribosyltransferase (NAMPT), with IC50 values of 14.93 nM and 12.56 nM, respectively. This compound effectively induces apoptosis, making it a valuable tool for research into cancer mechanisms and treatment strategies. Additionally, Mutant IDH1/NAMPT-IN-1 demonstrates the capability to cross the blood-brain barrier, enhancing its potential for applications in neurological studies and therapies.

Enasidenib mesylate is a selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzymes, demonstrating potent and reversible binding. It primarily exerts its biological activity by altering the metabolism of 2-hydroxyglutarate, thus affecting cellular processes associated with cancer progression. This compound is utilized in research focused on hematologic malignancies, particularly those driven by IDH2 mutations.